Russia’s biopharmaceutical company PSK Pharma has registered the first domestic drug with the active ingredient tirofiban for the treatment of acute coronary syndromes (ACS). A drug called Tirofiban PSK is a concentrate for the preparation of infusion solution, according to the data from the State Register of Medicines.
It is an antiplatelet agent from the group of antithrombotic drugs, most often used in cardiology departments for the treatment of patients with ACS. In this condition, due to the formation of blood clots in the coronary arteries, the blood supply to the heart muscle is disrupted, which increases the risk of myocardial infarction and other cardiovascular complications. Tirofiban PSK helps block the formation of blood clots and maintain normal blood flow in the coronary arteries, the press service of PSK Pharma explained. Tirofiban can also be used in combination with other antiplatelet drugs.
In early 2025, the Government of the Russian Federation granted PSK Pharma a compulsory license to manufacture the antibacterial drug Tedizolid. Now the company will not need the consent of foreign patent holders. The drug was supplied to Russia under the trade name Sivextro (included in the list of VED) until 2022, when the manufacturer stopped the deliveries.
